Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.41 |
| ▸ | USP2 | O75604 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8033008 | 0.91 | MTNR1A (0.42) | MTNR1AMTNR1BMAPK1USP2CYP1A2 | |
| SCHEMBL8263322 | 0.90 | MTNR1A (0.45) | MTNR1AMTNR1BMAPK1USP2CYP1A2 | |
| SCHEMBL8047092 | 0.87 | POLB (0.42) | MTNR1AMAPK1USP2KMT2AMAPT | |
| SCHEMBL12845349 | 0.84 | CDK2 (0.41) | MTNR1AMTNR1BMAPK1USP2CYP1A2 | |
| SCHEMBL13130721 | 0.84 | MTNR1A (0.41) | MTNR1AMTNR1BMAPK1USP2CYP1A2 | |
| SCHEMBL8048113 | 0.83 | MTNR1A (0.41) | MTNR1AMTNR1BMAPK1USP2CYP1A2 | |
| SCHEMBL8050446 | 0.81 | HTR2A (0.35) | USP2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8043495 | 0.81 | USP2 (0.49) | MTNR1AMTNR1BMAPK1USP2CYP1A2 | |
| SCHEMBL12845635 | 0.80 | CDK2 (0.41) | MTNR1AMTNR1BMAPK1USP2CYP1A2 | |
| SCHEMBL12810900 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583524-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-21 | — | — | US | disclosed |
| US-20200121667-A1 | Inhibitors Of The Interaction Between MDM2 And P53 | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-23 | — | — | US | disclosed |
| US-20170112818-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-27 | — | — | US | disclosed |
| US-20170112818-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-27 | — | — | US | disclosed |
| US-9573933-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-21 | — | — | US | disclosed |
| US-9573933-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-21 | — | — | US | disclosed |
| EP-2203440-B1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-23 | — | — | EP | disclosed |
| US-20100240637-A1 | Inhibitors of the Interaction Between MDM2 and P53 | JANSSEN PHARMACEUTICAL NV (BE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240637-A1 | Inhibitors of the Interaction Between MDM2 and P53 | JANSSEN PHARMACEUTICAL NV (BE) | 2010-09-23 | — | — | US | disclosed |
| WO-2009037308-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240637-A1 | Inhibitors of the Interaction Between MDM2 and P53 | TP53, MDM2, TP53BP1 | MTNR1A 1006/4885MTNR1B 1771/4885MAPK1 2280/4885 |
| US-20170112818-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | TP53, MDM2, TP53BP1 | MTNR1A 1006/4885MTNR1B 1771/4885MAPK1 2280/4885 |
| US-11583524-B2 | Inhibitors of the interaction between MDM2 and P53 | TP53, MDM2, TP53BP1 | MTNR1A 1006/4885MTNR1B 1771/4885MAPK1 2280/4885 |
| US-20200121667-A1 | Inhibitors Of The Interaction Between MDM2 And P53 | TP53, MDM2, TP53BP1 | MTNR1A 1118/4885MTNR1B 1821/4885MAPK1 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.